Market Closed -
Nasdaq
01:30:00 26/06/2024 am IST
|
5-day change
|
1st Jan Change
|
7.25
USD
|
-3.59%
|
|
-1.63%
|
+11.71%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
178.6
|
504.1
|
401
|
486.4
|
-
|
-
|
Enterprise Value (EV)
1 |
130.9
|
360.8
|
321.1
|
266.7
|
287.1
|
218
|
P/E ratio
|
-3.2
x
|
-6.1
x
|
-5.11
x
|
-5.29
x
|
-5.23
x
|
-5.84
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
179
x
|
-
|
-
|
249
x
|
192
x
|
414
x
|
EV / Revenue
|
131
x
|
-
|
-
|
137
x
|
113
x
|
186
x
|
EV / EBITDA
|
-2.65
x
|
-5.86
x
|
-3.14
x
|
-2.4
x
|
-2.44
x
|
-1.69
x
|
EV / FCF
|
-3.11
x
|
-7.31
x
|
-4.76
x
|
-2.91
x
|
-3
x
|
-1.91
x
|
FCF Yield
|
-32.2%
|
-13.7%
|
-21%
|
-34.4%
|
-33.4%
|
-52.3%
|
Price to Book
|
1.11
x
|
1.32
x
|
1.81
x
|
1.85
x
|
2.68
x
|
2.58
x
|
Nbr of stocks (in thousands)
|
25,267
|
49,516
|
61,795
|
64,677
|
-
|
-
|
Reference price
2 |
7.070
|
10.18
|
6.490
|
7.250
|
7.250
|
7.250
|
Announcement Date
|
03/03/22
|
27/03/23
|
14/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
1
|
-
|
-
|
1.95
|
2.533
|
1.175
|
EBITDA
1 |
-
|
-36.63
|
-49.35
|
-61.54
|
-102.3
|
-111.3
|
-117.6
|
-128.7
|
EBIT
1 |
-70.2
|
-37.02
|
-49.86
|
-62.03
|
-102.6
|
-111
|
-124
|
-136.6
|
Operating Margin
|
-
|
-
|
-4,986%
|
-
|
-
|
-5,694.64%
|
-4,893.33%
|
-11,627.12%
|
Earnings before Tax (EBT)
1 |
-
|
-39.76
|
-49.65
|
-59.99
|
-89.97
|
-100.6
|
-121.8
|
-142.4
|
Net income
1 |
-
|
-29.35
|
-50.16
|
-60.34
|
-90.21
|
-100.7
|
-121.8
|
-142.4
|
Net margin
|
-
|
-
|
-5,015.8%
|
-
|
-
|
-5,164.56%
|
-4,807.07%
|
-12,123.06%
|
EPS
2 |
-26.74
|
-102.9
|
-2.210
|
-1.670
|
-1.270
|
-1.370
|
-1.386
|
-1.241
|
Free Cash Flow
1 |
-
|
-30.39
|
-42.17
|
-49.38
|
-67.44
|
-91.78
|
-95.76
|
-114
|
FCF margin
|
-
|
-
|
-4,216.7%
|
-
|
-
|
-4,706.48%
|
-3,779.91%
|
-9,700%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/20
|
30/03/21
|
03/03/22
|
27/03/23
|
14/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
2.34
|
-
|
-
|
EBITDA
1 |
-13.76
|
-13.68
|
-13.95
|
-17.18
|
-16.74
|
-24.08
|
-21.09
|
-33.11
|
-23.99
|
-25.38
|
-27
|
-29
|
-30
|
-
|
-
|
EBIT
1 |
-13.88
|
-13.82
|
-14.08
|
-17.29
|
-16.83
|
-24.16
|
-21.16
|
-33.18
|
-24.06
|
-25.45
|
-27.86
|
-32.56
|
-29.11
|
-27.48
|
-25.54
|
Operating Margin
|
-1,387.8%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,243.97%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-13.81
|
-13.75
|
-13.92
|
-16.81
|
-15.5
|
-21.47
|
-17.82
|
-29.71
|
-20.97
|
-22.28
|
-24.5
|
-26
|
-27.5
|
-
|
-
|
Net income
1 |
-14.25
|
-13.77
|
-13.93
|
-16.82
|
-15.82
|
-21.47
|
-17.9
|
-29.77
|
-21.02
|
-22.37
|
-24.51
|
-26.01
|
-27.51
|
-
|
-
|
Net margin
|
-1,424.8%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,175.53%
|
-
|
-
|
EPS
2 |
-0.5600
|
-0.5500
|
-0.5500
|
-0.4400
|
-0.2900
|
-0.3100
|
-0.2500
|
-0.4200
|
-0.2900
|
-0.3000
|
-0.3375
|
-0.3400
|
-0.3425
|
-0.2992
|
-0.2878
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
03/03/22
|
16/05/22
|
08/08/22
|
09/11/22
|
27/03/23
|
15/05/23
|
08/08/23
|
14/11/23
|
14/03/24
|
13/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
62
|
47.7
|
143
|
79.9
|
220
|
199
|
268
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-30.4
|
-42.2
|
-49.4
|
-67.4
|
-91.8
|
-95.8
|
-114
|
ROE (net income / shareholders' equity)
|
-
|
-234%
|
-27.6%
|
-33.9%
|
-35%
|
-38.9%
|
-42.7%
|
ROA (Net income/ Total Assets)
|
-50.5%
|
-38.5%
|
-26.5%
|
-32.5%
|
-33.4%
|
-42.6%
|
-62.6%
|
Assets
1 |
58.1
|
130.2
|
227.5
|
277.8
|
301.5
|
285.9
|
227.5
|
Book Value Per Share
2 |
-412.0
|
6.340
|
7.690
|
3.580
|
3.910
|
2.710
|
2.810
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.58
|
0.34
|
0.28
|
0.05
|
0.75
|
0.7
|
0.73
|
Capex / Sales
|
-
|
34%
|
-
|
-
|
38.24%
|
27.57%
|
62.1%
|
Announcement Date
|
30/03/21
|
03/03/22
|
27/03/23
|
14/03/24
|
-
|
-
|
-
|
Last Close Price
7.25
USD Average target price
14.21
USD Spread / Average Target +96.06% Consensus |
1st Jan change
|
Capi.
|
---|
| +11.71% | 486M | | +38.36% | 52.5B | | +36.73% | 39.31B | | -8.63% | 39.01B | | +25.46% | 28.2B | | -11.17% | 26.57B | | +11.44% | 26.2B | | +45.09% | 14.15B | | +32.93% | 12.62B | | -5.30% | 11.74B |
Other Biotechnology & Medical Research
|